Heart valve calcification and @entity460 x XXXX product in hemodialysis @entity1 : analysis of optimum values for its prevention.

@entity1 @entity6 @entity7874 @entity26104 @entity460 @entity16415 @entity12525 @entity3151 @entity461 @entity165 @entity454
BACKGROUND: Prevalence of @entity7874 ( @entity7874 ) in @entity454 ( @entity454 ) @entity1 is high and information regarding modifiable predictors is scarce. Our aim was to determine the prevalence of @entity7874 in our maintenance hemodialysis (HD) population, and the optimal Ca x P value that most accurately predicted the presence of @entity7874 after controlling for comorbidities. METHODS: This was a cross-sectional observational study of a cohort of 52 stable @entity1 on maintenance HD for more than 12 months. Mean 12 months serum biochemical data ( @entity460 , @entity3151 , @entity461 , lipids) and M-mode 2D echocardiogram were used to evaluate the presence or absence of mitral and aortic @entity7874 and ventricular geometry. RESULTS: Twenty @entity1 (38.4%) presented with @entity7874 . @entity1 with @entity7874 were more commonly @entity6 and showed higher levels of serum @entity3151 , Ca x P product, total and LDL @entity165 , and poor ventricular geometry, as compared to @entity1 without @entity7874 . Moreover, they required higher doses of both @entity16415 and @entity12525 . Logistic regression analysis showed that @entity7874 was independently influenced by age, Ca x P, and @entity6 . ROC curves illustrated that a Ca x P>43 mg2/ @entity26104 was the optimal value in terms of sensitivity and specificity for predicting the presence of @entity7874 in our @entity1 population. CONCLUSION: These findings highlight the importance of applying more vigorous measures for Ca x P control.
